The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly improved survival benefits. However, the clinical benefits of targeting ALK using TKIs are limited due to the emergence of dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yue, Deng, Chao, Qiu, Zhenhua, Cao, Chenghui, Wu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517331/
https://www.ncbi.nlm.nih.gov/pubmed/34660278
http://dx.doi.org/10.3389/fonc.2021.713530
_version_ 1784583993158533120
author Pan, Yue
Deng, Chao
Qiu, Zhenhua
Cao, Chenghui
Wu, Fang
author_facet Pan, Yue
Deng, Chao
Qiu, Zhenhua
Cao, Chenghui
Wu, Fang
author_sort Pan, Yue
collection PubMed
description Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly improved survival benefits. However, the clinical benefits of targeting ALK using TKIs are limited due to the emergence of drug resistance. The landscape of resistance mechanisms and treatment decisions has become increasingly complex. Therefore, continued research into new drugs and combinatorial therapies is required to improve outcomes in NSCLC. In this review, we explore the resistance mechanisms of ALK TKIs in advanced NSCLC in order to provide a theoretical basis and research ideas for solving the problem of ALK drug resistance.
format Online
Article
Text
id pubmed-8517331
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85173312021-10-16 The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer Pan, Yue Deng, Chao Qiu, Zhenhua Cao, Chenghui Wu, Fang Front Oncol Oncology Anaplastic lymphoma kinase (ALK) is a validated molecular target for non-small-cell lung cancer (NSCLC). The use of tyrosine kinase inhibitors (TKIs) has led to significantly improved survival benefits. However, the clinical benefits of targeting ALK using TKIs are limited due to the emergence of drug resistance. The landscape of resistance mechanisms and treatment decisions has become increasingly complex. Therefore, continued research into new drugs and combinatorial therapies is required to improve outcomes in NSCLC. In this review, we explore the resistance mechanisms of ALK TKIs in advanced NSCLC in order to provide a theoretical basis and research ideas for solving the problem of ALK drug resistance. Frontiers Media S.A. 2021-10-01 /pmc/articles/PMC8517331/ /pubmed/34660278 http://dx.doi.org/10.3389/fonc.2021.713530 Text en Copyright © 2021 Pan, Deng, Qiu, Cao and Wu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Pan, Yue
Deng, Chao
Qiu, Zhenhua
Cao, Chenghui
Wu, Fang
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
title The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
title_full The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
title_fullStr The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
title_full_unstemmed The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
title_short The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
title_sort resistance mechanisms and treatment strategies for alk-rearranged non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517331/
https://www.ncbi.nlm.nih.gov/pubmed/34660278
http://dx.doi.org/10.3389/fonc.2021.713530
work_keys_str_mv AT panyue theresistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT dengchao theresistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT qiuzhenhua theresistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT caochenghui theresistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT wufang theresistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT panyue resistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT dengchao resistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT qiuzhenhua resistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT caochenghui resistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer
AT wufang resistancemechanismsandtreatmentstrategiesforalkrearrangednonsmallcelllungcancer

Ejemplares similares